Fosun Pharma Awarded "China's Most Innovative Pharmaceutical Enterprise"

Artesunand Parkinson Disease Tablet Received Recognition in the Industry

HONG KONG, June 25, 2013 /PRNewswire/ -- Shanghai Fosun Pharmaceutial (Group) Co. Ltd.("Fosun Pharma" or the "Company"; stock code: 600196-SH, 02196-HK; and, together with its subsidiaries, the "Group"), a leading healthcare company in the PRC, announced that the Company was awarded "China's Most Innovative Pharmaceutical Enterprise". Meanwhile, its three-vial pack of Artesun 30mg and 120mg passed the pre-qualification of World Health Organization (WHO). In addition, "Rasagiline Transdermal Patch", its new drug targeted to cure Parkinson's Disease (PD), has been approved by China Food and Drug Administration (CFDA) for Clinical trial recently.

In recent years, Fosun Pharma's main business development strategy has been increasingly prominent, its pharmaceuticals core research and innovative capacity are well recognized. The Company ranked sixth in the CFDA Southern Medicine Economic Institute's selection of "Top Ten Most Innovative Pharmaceutical Enterprises". With a candidate pool based on the "Top 100 Pharmaceutical Companies in China", the ten companies with the highest composite scores are selected as the "China's Most Innovative Pharmaceutical Enterprises". This award reaffirms Fosun Pharma's outstanding research capacity and market position.

Recently, the 30mg and 120mg new standard products of Artesun, a specialty medicine line targeted to cure severe malarial manufactured by Guilin Pharma, Fosun Pharma's subsidiary passed the pre-qualification of WHO. As a globally recognized injectable Artesunate research enterprise and the only injectable Artesunate manufacturer approved by WHO, Guilin Pharma does not only commit to product quality and stable market supply, it also targets the market demand affected by the epidemic and developed the 30mg and 120mg standard products for infant and adult respectively. Furthermore, Artesun are produced in individual packs (powder injection, solvent and lacquer thinner), which can be easily adapted in Africa regions with poor medical conditions.Dr. Timothy Wells, Chief Scientific Officer of Medicines for Malaria Venture, said, "The pre-qualification of injectable Artesunate 30mg and 120mg by WHO means a lot to children and adult in Africa who are living in heavily-infected areas. Hopefully, this new treatment will be used extensively in the global battle against malaria and will completely eliminate this epidemic."

Moreover, "Rasagiline Transdermal Patch", a State Category II Chemical New drug targeted to cure PD produced by Chongqing Pharmaceutical Research Institute Co., Ltd. has been approved by CFDA for Clinical trial recently. "Rasagiline" is an international first-line drug, it has been launched in Israel, United Kingdom, Ireland, Germany, Austria, Denmark, Finland, and the United States and etc. As of now, the drug filed 5 invention patents and one of them has been granted. In addition, the drug obtained patent invention authorization in European Union, Australia, Russia, and Canada, and is expected to get new drug certificates in 2016.

Mr. Chen Qiyu, Chairman of Fosun Pharma, said, "We are honored for receiving 'China's Most Innovative Pharmaceutical Enterprises', Fosun Pharma always takes independent innovation as the driving force for corporate development. In China, Fosun Pharma has achieved competitive advantage for the market segments of liver disease, diabetes, tuberculosis and clinical diagnostic products; while in the global market, Fosun Pharma has also become a market leader in antimalarial drug. As biopharmaceutical market has become a main competition in the worldwide pharmaceutical field, Fosun Pharma is committed to building a leading biomedical research and development regime in China."

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosun Pharma is a leading healthcare company in the PRC. The Group was established in 1994 with headquarters located in Shanghai, and was listed on the Shanghai Stock Exchange in 1998. In October 2012, the Company successfully completed offering and listing H shares in Hong Kong. As a result, the Company has listings in both the A share market and the H share market. The Group has achieved significant results with strengthened corporate governance and investor relationship management. In addition to the SSE 180 Index, CSI 300 Index, SSE Dividend Index and SSE Corporate Governance Index, Fosun Pharma is also included in the SSE Private Enterprise 50 Index and SSE Social Responsibility Index. According to IMS Health Incorporated ("IMS"), the Group was one of the top five domestic pharmaceutical companies in the PRC by revenue in the pharmaceutical manufacturing segment in 2011. The Group's business operations strategically cover multiple important segments in the healthcare industry value chain, with business segments including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services and diagnostic products and medical devices.

Additional information about Fosun Pharma is available at http://www.fosunpharma.com.

For further information, please contact:

Porda Havas International Finance Communications Group